Skip to main content
Clinical Trials/NCT03308084
NCT03308084
Completed
Phase 3

Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion

Rush University Medical Center0 sites105 target enrollmentNovember 13, 2015

Overview

Phase
Phase 3
Intervention
Dexamethasone
Conditions
Dysphasia
Sponsor
Rush University Medical Center
Enrollment
105
Primary Endpoint
Postoperative Pain
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to determine if the frequency and duration of postoperative pain are improved in participants receiving a local steroid injection (methylprednisolone) plus a systemic (intravenous (IV, by vein)) steroid (dexamethasone) when compared to those receiving a systemic (IV) steroid (dexamethasone) alone. Both of these steroid injections are already currently used at Rush and are considered standard of practice. It is well established that steroids have an anti-inflammatory (decreased swelling) effect on the soft tissue and it is routinely used in many types of surgery, but it is not known whether two steroids are better than one. The medications provided in this study are approved by the Food and Drug Administration (FDA).

Detailed Description

Postoperative pain is a well-known complication following minimally invasive transforaminal lumbar interbody fusion (MIS TLIF). It has been found that up to 40% of lumbar spinal patients will have either recurrent or persistent postoperative pain. Several studies have demonstrated reduced patient reported pain scores following steroid administration. However, few studies have investigated intraoperative local injection of corticosteroid at the surgical site in an effort to reduce the incidence and duration of postoperative pain for MIS TLIF patients. The purpose of this study is to determine if the incidence and duration of postoperative pain is improved in participants receiving a local injection of methylprednisolone with systemic dexamethasone when compared to those receiving the usual systemic dexamethasone undergoing MIS TLIF. The investigators hypothesize that participants undergoing MIS TLIF who receive local methylprednisolone along with the systemic dexamethasone will have: 1. Reduced incidence and duration of postoperative pain compared to participants receiving only systemic dexamethasone. 2. Shorter hospital stay compared to participants receiving only systemic dexamethasone. 3. Better short- and long-term outcomes compared to participants receiving only systemic dexamethasone

Registry
clinicaltrials.gov
Start Date
November 13, 2015
End Date
May 3, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kern Singh

Professor, Department of Orthopaedic Surgery

Rush University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing a primary 1- to 2-level MIS TLIF
  • Diagnosis: myelopathy, radiculopathy, myeloradiculopathy, stenosis, herniated nucleus pulposus, degenerative disc disease, spondylosis, osteophytic complexes, and foraminal stenosis
  • Patients able to provide informed consent

Exclusion Criteria

  • Allergies or other contraindications to medicines in the protocol including:
  • (a) Existing history of gastrointestinal bleeding
  • Current Smokers
  • Lumbar spine trauma
  • Bilateral cages
  • Lack of consent

Arms & Interventions

IV dexamethasone

Standard systemic (IV) dexamethasone only

Intervention: Dexamethasone

Local Depomedrol plus IV dexamethasone

Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone

Intervention: Methylprednisolone

Local Depomedrol plus IV dexamethasone

Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone

Intervention: Dexamethasone

Outcomes

Primary Outcomes

Postoperative Pain

Time Frame: 2 years postoperative

Change in Visual Analogue Scale Back and Leg score from preoperative value will be assessed

Secondary Outcomes

  • Physical Functioning(2 years postoperative)
  • Disability(2 years postoperative)
  • General health status(2 years postoperative)
  • Narcotic Consumption(1 week postoperative)
  • Length of Stay(1 week postoperative)
  • Intra-operative adverse events(day of surgery)
  • Post-operative adverse events(1 week postoperative)

Similar Trials